Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
Study identifier:MB001-078
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
Medical condition
Diabetes mellitus type 2
Phase
-
Healthy volunteers
No
Study drug
Exenatide
Sex
All
Actual Enrollment
1711
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Feb 2009
Primary Completion Date: 01 Mar 2014
Study Completion Date: 01 Mar 2014
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Group1:Type 2 diabetic patients treated with Exenatide therapy Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label | - |
Contacts
Contact Backup
First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time
-
-
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
